Organigram Holdings (OGI) reports Q2 2026 earnings: $59.8M revenue, 9% decline, but projects $350M for FY with Sanity acquisition.
Key Takeaways
- Net revenue for Q2 reached $59.8 million, a 9% decline year-over-year from $65.6 million in the previous year.
- Adjusted EBITDA stood at $0.9 million, down from $4.9 million in Q2 of the prior year.
- The company is experiencing an 18% year-over-year increase in international sales, with Q2 revenue for international markets at $6.1 million.
- Following the acquisition of Sanity Group, management adjusted fiscal 2026 guidance, projecting net revenue to exceed $350 million.
- The company retains its position as the number one licensed producer in Canada by market share, with significant growth in Quebec.
Financial Performance
In its Q2 2026 earnings call, Organigram Holdings Inc. reported several notable figures that reflect both its challenges and its areas of strength. Net revenue declined to $59.8 million, a 9% drop compared to $65.6 million in Q2 2025. This downturn was primarily attributed to share erosion in vapes and infused pre-rolls. The company's adjusted gross margin for the quarter was 31%, a decrease of 200 basis points year-over-year, largely due to the increased proportion of lower-value products in its portfolio.
Despite these challenges, the company reported a record quarterly harvest of over 32,000 kg, supported by improvements in cultivation yields. The average total farm cost (TFC) at its Moncton facility reached 29.8%, marking the highest level to date. Additionally, international sales increased from $5 million in Q1 to $6.1 million in Q2, reflecting the company's efforts to improve its international flower specifications and capture new markets.
Strategic Initiatives
The earnings call highlighted several strategic initiatives aimed at addressing market challenges and enhancing product offerings. The company has tightened quality control processes and made operational changes to improve the consistency of its products, particularly in pre-roll production. Management indicated that these improvements are already visible, with more consistent fill rates and better product quality expected in the upcoming quarters.
To address the decline in market share in the vape segment, Organigram is set to launch higher potency products and refresh its hardware offerings. This includes the introduction of Bachtop Liquid diamond all-in-ones, catering to shifting consumer preferences toward higher potency formats. Moreover, the company is actively expanding its product lineup in edibles and beverages, with notable successes in new product launches like Shred Shots and Shredom's Max 10s.
A significant highlight from the call was the completion of the Sanity Group acquisition, which positions Organigram to leverage growth opportunities in both Canada and Germany, the world's two largest federally legal cannabis markets. Sanity is expected to generate approximately €25 million in quarterly revenue over the next year, contributing significantly to Organigram's financial performance.
Future Outlook
Looking forward, management expressed optimism about the company’s trajectory for the second half of fiscal 2026. The adjusted guidance projects a net revenue exceeding $350 million, driven by higher sales from both domestic operations and the integration of Sanity Group. The company's confidence is further bolstered by expected improvements in product quality and market conditions, with management anticipating a material step change in international growth as they continue to enhance product specifications.
Despite the current challenges, the company is confident in its ability to regain market share and drive stronger growth. The introduction of new products and an improvement in operational execution are expected to stabilize performance across impacted segments. Management also highlighted the potential benefits from the anticipated EU GMP certification, which will enhance their standing in international markets.
In terms of competitive positioning, while the market has experienced some softness, especially in Ontario, Organigram aims to capitalize on its leading market share and strong brand portfolio. With brands like Shred, Box Hot, and Big Bag of Buds ranking among the top nationally, the company is well-positioned to respond to competitive pressures and changing consumer demands.
Closing Assessment
In conclusion, while Organigram Holdings Inc. is navigating a challenging landscape with declining revenues and increased competition, its strategies for operational improvements, innovation, and international expansion present a promising path forward. The acquisition of Sanity Group provides a substantial opportunity for growth in a burgeoning market, and management's proactive measures to enhance product quality and market responsiveness are critical in regaining competitive advantages. As the company moves into the latter half of fiscal 2026, investors should watch for the realization of these strategic initiatives and the potential for recovery in both revenue and market share.
This analysis is based on public earnings call materials and is not investment advice.
